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Abstract 
Objectives: Osteoarthritis (OA) is a common chronic condition in older people but its 
association with other chronic conditions is largely unknown. This study aimed to 
systematically review the literature on comorbidities in people with OA compared to those 
without. 
Methods:  We searched four databases for observational studies on comorbidities in people 
with OA. Studies of OA only or in comparison with non-OA controls were included.  Risk of 
bias and study quality was assessed using the Newcastle-Ottawa Scale (NOS). The 
prevalence of comorbidities in the OA group and prevalence ratio (PR) and 95% confidence 
interval (CI) between OA and non-OA groups were calculated. 
Results: Forty-two studies from 16 countries (27 case-only and 15 comparative studies) met 
the inclusion criteria.  Mean age of participants varied from 51 to 76 years.  Pooled 
prevalence of any comorbidity was 67% (95%CI: 57%-74%) in people with OA versus 56% 
(95%CI: 44%-68%) in people without OA. The pooled PR for any comorbidity was 1.21 
(95%CI: 1.02-1.45).  The PR increased from 0.73 (95%CI: 0.43-1.25) for one comorbidity, to 
1.58 (95%CI: 1.03-2.42) for two, and 1.94 (95%CI 1.45- 2.59) for three or more 
comorbidities. The key comorbidities associated with OA were stroke (PR 2.61; 95%CI: 
2.13-3.21), peptic ulcer (PR 2.36; 95%CI: 1.71-3.27) and metabolic syndrome (PR 1.94; 
95%CI 1.21-3.12). 
Conclusions: People with OA are more likely to have other chronic conditions.  The 
association is dose-dependent in terms of the number of comorbidities, suggesting 
multimorbidities. Further studies on the causality of this association and clinical implications 
are needed. 
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Significance and Innovations 
This is the first systematic review of the current literature on comorbidities in OA with an 
extensive list of the conditions. 
The key findings are:  
[1] 67% of people with OA have at least one other chronic condition, which is 20% higher 
than people without OA;  
[2] there was a graded effect in terms of the risk of having one, two and three or more 
comorbidities in people with OA compared to those without;  
[3] in people with OA, the systems most likely to be affected by comorbidities are upper 
gastrointestinal, psychological, cardiovascular and endocrine; 
[4] stroke, peptic ulcer and metabolic syndrome are the most common comorbidities 
 
INTRODUCTION 
Osteoarthritis (OA) is by far the most common form of arthritis and is a  major cause of pain 
and disability in older people. (1) It is a common complex disorder with multiple genetic, 
constitutional and environmental risk factors. (2) Presence of multiple chronic conditions in a 
single person causes higher mortality, increased hospitalization, impaired  physical and 
mental health, worse disease outcome and poorer quality of life. (3,4) Co-existence of chronic 
conditions with OA is also very common, especially in the later decades of life. (5,6) For 
example, according to the  Centre for Disease Control (CDC, Atlanta), more than 30% of 
people with diabetes and heart disease have OA. (7)  
Most literature on OA comorbidity were published in the last three years. The  review articles 
focused on  the distribution and impact of individual chronic condition such as cardio-
vascular diseases, diabetes and depression in OA.(8–11) Even though comorbidity was 
discussed as a concept in the 1960s, it was only in 1996 that a distinct definition was first 
suggested to differentiate “comorbidity” (implying an index disease with mechanistically 
linked additional conditions) and “multimorbidity” (implying any co-occurrence of medical 
conditions) within a person. (12) Comorbidity research in OA is still at a preliminary stage 
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A  systematic review on OA reported worsening of pain and decline in functional activities  
among people due to the presence of other chronic conditions. (13) Clinically, comorbidities 
in OA create greater challenges for management. The number and pattern of different 
comorbid conditions determine the severity and burden in multimorbid 
patients.(14,15)However , except for shared risk factors such as ageing and obesity, little is 
known about biological plausibility to explain concurrence of OA and associated 
comorbidities.(16,17) According to the European League Against Rheumatism (EULAR) and 
National Institute for Health and Care Excellence (NICE), the diagnosis and management of 
specific comorbidities and understanding their pattern in OA are important and are 
recommended for best practice. (18,19) An Arthritis Research UK (ARUK) report on  
multimorbidity in OA also highlighted the importance of understanding the presence of 
multiple comorbidities with OA for formulating a ‘patient-centred’ management plan. (20) 
This study aimed to systematically review the current literature on the comorbidities in OA, 
specifically, the risk (prevalence or incidence) of comorbidities in people with OA compared 
to those without OA.   
 
METHODS 
A protocol adhering to the Preferred Reporting Items for Systematic review and Meta-
Analysis (PRISMA), 2015 statement was designed and registered online (PROSPERO 2016: 
CRD42016038484).  
 
Search methods and sources 
Electronic searches: MEDLINE, PubMed, EMBASE and Scopus database were used to 
identify studies conducted in any countries between 01-January-1995 and 31-December-
2017. Additionally, “comorbidity in OA” was searched in ‘Google scholar’ search engine and 
the first 1000 articles were screened for inclusion. The complete search consisted of: [1] 
searches for OA (any joint); [2] search for co-morbidities; and [3] searches for observational 
studies. The three search strategies were then combined using ‘AND’ to generate citations. 
The details of the search strategies can be seen in Appendix A1. In addition websites of 
international  societies on arthritis such as EULAR, the American College of Rheumatology 
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(18,21,22) References within systematic reviews and review articles were also read for 
additional relevant original articles.  
Selection criteria  
Types of studies: All types of observational studies (with or without a non-OA control) 
documenting prevalence or incidence, and risk ratio of OA comorbidity were included in the 
study. We defined ‘comorbidity’ as presence of any concurrent chronic condition in people 
with OA (as an index disease).  
Participants: Studies on people with OA diagnosed by a physician through physical 
examination or radiographic findings. Exposure: OA was the primary exposure. Outcomes: 
presence of any comorbidities.  Other comparisons: studies comparing prevalence/incidence 
of comorbidities in OA with non-OA control (comparative) and studies of comorbidities in 
people with OA (case-only) were included.  
According to the above criteria, all studies identified by title and abstract were gathered and 
duplicates were removed. Potentially relevant articles were selected through initial title and 
abstract screening by two authors [SS and AS] independently. Any disagreement was 
discussed with WZ. The full text copies of these relevant articles were then retrieved. We 
retained articles that studied the prevalence of other chronic conditions in people with OA. 
Full texts of potentially suitable articles were further screened for inclusion by SS. 
Disagreement in the screening of full texts was resolved by a third reviewer [WZ]. There was 
no language limitation. We used Endnote for screening of articles; data extraction was done 
without using any software. 
Quality assessment   
One reviewer (SS) independently assessed study quality based on items in the Newcastle 
Ottawa Scale checklist (NOS).(23) Any concern on quality scoring was decided in 
consultation with another reviewer [AS or WZ]. The NOS tool has a scoring scale under three 
sections namely; participant selection and representativeness, comparability of study groups, 
and assessment of outcome or exposure. The quality score is based on a “star” system (range 
0-9 stars for case-control and cohort studies and from 0 to 10 for cross-sectional studies) with 
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 Data Extraction  
A customised data extraction form was used to extract data from each study. For each 
included study we collected following information: (1) authors and publication year; (2) title 
and journal; (3) study country and location (urban or rural); (4) study design; (5) sampling 
method (random or non-random); (6) sample size; (7) sample characteristics such as age and 
gender; (8) number of conditions included; (9) methods of comorbidity measurement; and 
(10) prevalence (overall and group specific for each comorbidity).  
Outcome 
The primary outcome was the risk (prevalence) of comorbidities in people with OA (cases) 
versus those without OA (controls), and secondary outcomes included the types of 
comorbidities associated with OA. Risk of having the comorbidity between OA and non-OA 
controls were estimated through prevalence ratio (PR), separately for all comparative studies 
and for age and sex matched/adjusted comparative studies. For cohort studies, the prevalence 
of comorbidities reported at the baseline was included for the estimation. Because in these 





Descriptive characteristics of the studies are expressed as means/medians and/or frequencies 
as appropriate depending on the variables. For comorbidity count we used median because of 
wider variation in the list of the diseases across the studies. Heterogeneity between studies 
was measured using the I
2
 (%) and Q test [p value]. (24,25) Publication bias was assessed 
using funnel plots and Egger’s test with statistical significance being conferred to P< 0.05. 
(26) For heterogeneity, I2 above 75% was considered as wider heterogeneity, demanding 
careful interpretation of the findings. (25) Prevalence and prevalence ratio (PR) and 95% 
confidence intervals (CI) were calculated wherever possible for each comorbidity. The PR 
was chosen over odds ratio (OR) because that we had prevalence data for both OA cases 
(exposure) and non-OA controls (non-exposure).  In this scenario PR is recommended over 
OR to  minimise the overestimation of the relative risk. (27) For prevalence estimation, 
subgroup analysis was done according to the study design (cross sectional, case-control and 
cohort). For PR, however, only one article had different study design from others thus not 
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subgroup analysis was done as per the (NOS). We used the median NOS score (6) as a cut-off 
for grouping the studies. In order to remove the impact of age and sex, the association of 
disease specific and system specific comorbidities analysis was done for all the comparative 
studies and for “age-sex matched control’ comparative studies. The results across different 
studies were  pooled using random effects meta-analysis METAPROP package (28), an 
additional function of STATA  (V15, Stata Corp LP, College Station, TX, USA) (29) and 
Revman V 5.3. (30) 
 
RESULTS 
Search results and study qualities 
The initial search yielded 70,014 articles from four databases. After removal of duplicates 
48,661 remained, of which 1,091 appeared relevant after title screening. Abstract reading 
confirmed 56 relevant articles and full text papers which were fully assessed. Forty-two 
articles met the inclusion criteria (Figure-1). On the quality assessment scale (maximum of 
10) for cross sectional studies (n=33), the average score was 5.44 (median=6), and of them, 
22 studies (31–52) had 5 stars or more. Five case-control and four cohort studies had an 
average score of 5.22 (range 0-9), with six studies (6,33,53–56) having five stars or more. 
(Appendix A2)  
Study characteristics  
Of the 42 included studies, 15 compared comorbidities between people with OA and those 
without (comparative studies) whereas 27 examined comorbidities in people with OA only ( 
case-only studies). These included three case-control studies  (6,57,58), six cohort studies  
(53–56,59,60) and 33 cross-sectional studies that explored comorbidity in people with OA 
(1,5,31–52,61–70) (Table-1). We used the baseline comorbidity information from the cohort 
studies. Thus, we could calculate prevalence only for the comorbidities. Twelve studies were 
from the USA (32,34–40,53,57,63,65), nine from the Netherlands (1,33,41–44,54,55,59,60), 
four from the United Kingdom (6,45,46,66), two each from Finland (47,48), Japan (49,56) and 
Italy  (61,67) and one each from Canada (50), Hong Kong (5), Spain (68), Australia (51), South 
Korea (52), Germany (31), Turkey (62), India (69), Brazil (70), Iraq (58) and Latin America 
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based on national insurance data (32,57) and 28 were hospital-based studies. Eleven studies 
collected information on knee  OA (5,37,49,52,53,56–58,62,68,69), two were on hip OA (47,63), 
14 were on both knee and hip OA (1,6,33,39,41,42,45,54,55,55,60,66,67,71), one each on ankle 
(35), hand (43) and hip/knee/hand (61). Of 15 comparative studies, 12 had controls minimally 
matched for age and sex of OA cases. In the included studies OA was diagnosed in the 
following ways: clinician assessment without radiographic findings (n=24); clinical 
assessment with radiographic diagnosis (n=13 studies); self-reported physician given 
diagnosis (n=4) (40,45,51,65); and radiographic findings alone (n=1) (62). Details of the study 
characteristics are provided in Appendix B1.  
The mean age of the study participants varied from 50.8 years to 76.1 years across studies. 
The sample size of the included studies ranged from 91 to 237,172 (40,49) and included both 
men and women except one which had only women. (56) The detailed demographic 
information (age, sex, body mass index and obesity) is provided in Table-1.   
 
Prevalence of comorbidities 
Of 42 included studies, 15 case-only studies and 8 comparative studies had data on 
comorbidity count for analysis. The pooled prevalence of any chronic condition in all studies 
among people with OA was 66% (95%CI: 58%-74%). In OA cases, 29% of participants had 
a single comorbidity, 25% had two and 24% had three or more. Further subgroup wise 
prevalence across the study design is provided in Figure-2. High heterogeneity was observed 
across studies. Technical details of the data extraction are provided in Appendix A3 and A4.  
 The leading systems in terms of pooled prevalence in people with OA were cardiovascular 
(35%), musculoskeletal (34%), neurological (30%) and upper gastrointestinal (UGI) (19%). 
The leading chronic conditions reported among people with OA were hypertension (50%, 
95% CI: 36%-57%), dyslipidaemia (48%, 95% CI: 14%-66%) and back pain (33%, 95% CI: 
11% - 37%) followed by thyroid disorder (26%, 95% CI: 6%-68%) and depression (17%, 
95% CI: 12%-22%). The proportion of chronic conditions were reported to be higher in case-
control and cross-sectional studies compared to cohort studies. (Figure- 3) Details of the 
prevalence across the study designs are given in Appendix B2 and B3. All the included 
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Comparison between people with and without OA 
Forest plots for PR and 95%CI between OA and number of chronic conditions in comparative 
studies are shown in Figure-4. Eight studies reported the prevalence of comorbidities in 
people with OA and age and sex matched controls, which were used to estimate PR for 
matched studies. (6,34,44,45,49,56,64,65)  
The pooled PR for any comorbidity in studies matched by age and sex was 1.21 [95% CI: 
1.02-1.45, I
2
 = 100%, P <0.001]. The PR increased from 0.73 [95% CI: 0.43-1.25] for one 
comorbidity, to 1.58 [95% CI: 1.03-2.42] for two, and 1.94 [95% CI: 1.45-2.59] for three or 
more comorbidities in OA compared with non-OA people. [Figure-4] Subgroup analysis was 
done for the studies according to the NOS score (see Figure-4). Funnel plots for the studies 
are given in Appendix B4 and Eggers test reported non-significant publication bias (P value = 
0.72). 
The risks for having system specific comorbidities in age and sex matched/adjusted studies 
among OA people were significantly high for upper gastro intestinal (UGI) disorder [PR 
2.36; 95% CI: 2.31-2.41], psychological conditions [PR 1.75; 95% CI:1.20-2.54], and 
cardiovascular disease [PR 1.56; 95% CI: 1.34-1.86] compared to non-OA people. For 
specific diseases the risk of stroke was 2.61 [95% CI: 2.13-3.21] times higher among OA 
people compared to non-OA, followed by peptic ulcer [PR 2.36; 95% CI: 1.71-3.27] and 
metabolic syndrome [PR 1.94; 95% CI 1.21-3.12]. [Table 2]  
 
DISCUSSION  
To our knowledge, this is the first systematic review of the literature to examine the evidence 
of an extensive list of comorbidities in OA. Forty-two studies from 16 countries were 
included. The key findings are: [1] 67% people with OA had at least one other chronic 
condition, being 20% higher than those without OA; [2]  there was a graded effect in terms of 
the risk of having one, two, and three or more comorbidities in people with OA compared to 
those without; [3] the systems most likely to be affected by comorbidities in people with OA 
were upper GI, psychological, cardiovascular and endocrine; and [4] stroke, peptic ulcer and 
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Studies on multi-morbidity from both the developed and developing countries reported OA as 
a leading chronic condition. (14,15,72,73) The risk of having any comorbidities  in OA was 
reported to be 2.35 times more in the UK general practices population (46) and the risk for 
multimorbidity was three times higher in the Australian population compared to a non-OA  
group. (51)  The stronger association of number of comorbidities in OA indicates the 
existence of the problem of multimorbidity among these people. Besides the number, pattern 
of chronic conditions in OA influences management decisions. Comorbidities increase the 
complexity of care through increased exposure to the medication and other chronic 
conditions. However, the relationship of these factors with the comorbidities are yet to be 
discovered. This requires further research to explore the pattern and causality of 
comorbidities in OA. 
However, the risk of developing comorbidities in OA patients and their biological plausibility 
is not well investigated. Of the 42 studies included, only 12 primarily examined the 
comorbidity in OA, 15 had a comparative group and 27 were published in the years 2010-
2017.  This indicates the quality of the evidence and growing interest in OA comorbidity. 
Evidence on risk of having disease specific comorbidities is not well documented except for 
hypertension, diabetes and heart diseases and further less reported according to the system. 
(61)  Few studies are available to explain the association. For example, a meta-analysis done 
by Wang et al on the association of OA with cardiovascular diseases  reported  an association 
with RR of 1.24, which is less than  in our study. (9) Strong associations with other 
generalised and localised musculoskeletal conditions appear evident. (74,75) But whether co-
existence with respiratory diseases is independent or related was considered inconclusive 
(76), in contrast to our result. According to Parkinson et al, people with OA are at 1.41 times 
higher risk of getting diabetes. (77)  Nearly one fifth of OA patients have depression (11,78) 
but previous systematic reviews have been inconclusive about the extent of an 
association.(11) We report risks of eleven comorbidities among those with OA, which is 
more comprehensive than any previous study to date.  
Exploring factors for comorbidities can be difficult, as OA might share different common risk 
factors with different diseases. Presence of multiple comorbidities could be explained by 
ageing: an important risk factor for OA and other chronic conditions. But we found positive 
associations in age-matched comparative studies. Associations of OA with UGI diseases are 
well documented and usually attributed to long-term use of analgesics, particularly NSAIDs. 
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which necessitates correct diagnosis and reporting among patients with OA. Coexistence of 
cardiovascular comorbidities could be due to shared risk factors such as obesity and 
metabolic syndrome. (81,82) Besides those, NSAIDs and impaired physical activities in OA 
have been reported to increase risks of developing cardio-vascular disease.(82–85), Still, the 
causal association between OA and cardio-vascular disease is not well understood and could 
in part be attributable to genetic linkage. (87,88) For the association of OA with depression,  
hypothesize that the chronicity of the disease, pain, repeated health care utilization, health 
expenditure and functional limitation could be the drivers of depression among people having 
OA, and equally depression can influence pain experience. (78) Endocrine disorders such as 
hypothyroidism and diabetes could have an association with OA at specific joint sites (89), 
but lack of joint specific information and endocrine conditions in many studies limits our 
findings. We did not find fair evidence for musculoskeletal comorbidities in OA, even though 
reporting of similar age-related changes in other joints (90) or  muscle weakness or injury 
causing biomechanical derangement leading to pain (91). The increased reporting of back 
pain and migraine among both symptomatic OA and asymptomatic OA patients might reflect 
multiple regional pain resulting from altered pain physiology and central pain’ mechanisms. 
(92)  
Although we estimated the pooled prevalence, this needs careful interpretation owing to the 
large heterogeneity. However, this is only a systematic review of the current literature.  The 
purpose of this review is to identify a signal for future research, not to confirm the prevalence 
and the risk ratio. Prevalence reported in epidemiological studies are determined by the study 
design, sample size, case definition and the diagnostic method. The reported prevalence as 
per the system and disease indicates the existing burden of other chronic conditions in OA, 
which might affect care. Most of the chronic conditions are age related, thus understanding 
their coexistence across the age group could have been helpful. However, because of the 
limited articles available, we could not perform such subgroup analysis and limited our 
discussion to the association only. The heterogeneity of the studies and limited research 
highlights the need for better-quality comorbidity research in OA. 
There are several limitations to this study. Firstly, since multi-morbidity/comorbidity in OA 
is not well indexed in literature databases, we might have omitted some studies. Secondly, 
heterogeneity in prevalence estimates observed in our review, stemming from diversity of 
methodologies, might have caused uncertainty of the results. Thirdly, there was ambiguity in 
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and acidity should be considered separate entities. Fourthly, suboptimal information about 
OA reported in studies made it difficult to differentiate between structural OA and 
symptomatic OA, and to determine whether associations were linked primarily with structural 
OA or to pain experience. Similarly, the count of chronic conditions and the definition used 
varied considerably between studies and might have influenced the estimates. (93) Our 
comparative groups included any non-OA cases, so the comorbidity pattern might have been 
different because of selection of comparative/control groups, which needs to be interpreted 
with caution. Furthermore, unavailability of joint specific OA within comparative studies 
limited the estimation of joint specific comorbidities. Also, the study compiles data from 
different study designs thus has limitations in understanding the time sequences of OA with 
comorbidities. Unfortunately, there were not enough number of studies in each subgroup (one 
in cohort design) in comparative studies to perform subgroup analysis as per the study design. 
In conclusion, people with OA are 1.2 times more likely to have any comorbidity than non-
OA controls and 2.5 times more likely to have three or more comorbidities. The 
comorbidities with the highest increase in risk are stroke, peptic ulcer, hypertension and 
depression. Further research is needed to determine the causality between OA and these 
common comorbidities to optimise treatment and develop preventative strategies.  
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PATIENT CONSENT: No patients were directly included in the study (only in the primary 
studies of this review). 
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Table 1 Characteristics of included studies  
 
 Comparative studies 
(OA versus Non-OA) 
Case only studies 
 (OA only) 
Number of studies 15 27 
Total Study Participants 773,592 832,423 
Mean age in years [Range] 60.1[50.8-76.1] 63.9[54.1-74.0] 
Women% [95% CI] 53.0[35.0-70.0] 63.0[57.0-69.0] 
Body Mass Index; mean [Range] 
 (
#





   
Obesity prevalence, [95% CI] 
(
#





Comorbidities assessed*, Median [IQR] 
(
#








Knee 5 6 
Hip 0 2 
Ankle 1 0 
Both knee and hip 3 11 
Hand  0 1 
Any joint 5 6 
Hand, Hip and Knee                                    0 1 
Not given 1 0 
   
Methods of comorbidity measurement   
Charlson Comorbidity index 0 2 
Chronic Illness Rating Scale 1 3 
Simple Count 10 16 
Functional comorbidity assessment 1 0 
Self-Assessed Comorbidity Questionnaire 0 1 
Three methods 0 1 
Not mentioned 3 4 
Study settings   
Community Based 7 5 
Hospital Based 6 22 
Insurance data 2 0 
Methods of OA diagnosis   
Physician diagnosed 6 18 
Self-reported 3 1 
Radiographic 1 0 
Physician diagnosed and Radiographic 5 8 
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Table 2 Risk ratio of comorbidities associated with osteoarthritis (comparative studies) 
 








































































Endocrine 5 56125 58496 1.26[1.14-
1.39] * 
76 [0.002] 3 52257 52662 1.18[1.13-
1.23] * 
16 [0.30] 




1 11375 11780 1.14[1.07-
1.22] * 
NA 











3 55809 57887 1.11[1.00-
1.24]  















2 124326 124371 2.36[1.71-
3.27] * 






2 316 597 1.60[1.20-
2.13] * 




Vascular Disease  









Depression 4 129817 139895 1.94[1.62-
2.32] * 








2 113016 113016 1.57[1.55-
1.58] * 
0 [0.93] 









COPD/Asthma  3 55809 57887 1.45[1.21-
1.74] * 
























Diabetes  4 44750 46716 1.17[1.13-
1.21] * 
0 [0.55] 2 40882 40882 1.25[0.87-
1.78] 
26 [0.25] 




1 11375 11780 0.98[0.87-
1.10]  
NA 
*P Value<0.05 ; Pheter – P value for heterogeneity test 
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Figure legends  
Figure-1 PRISMA Flow of study selection  
Figure 2 Prevalence of number of any comorbidities in people with OA across the study design 
Figure 3 Prevalence of comorbidities in people with OA (disease and system specific) 















OA as not an index disease, n= 3 
Conference Abstracts, n= 11 
Study protocol, n =1 
 
 
Total citations retrieved, n= 70014 
Scopus, n= 12,247 
EMBASE, n= 17010 
Medline (ovid), n=19408 
PubMed, n= 21349 
Records after duplicates removed 
(n=48661) 
Records screened for title and 
abstract (n=1091) 
Articles assessed for eligibility 
based upon title and abstract 
(n=71) 
Records excluded, n= 47570 
Not relevant  
 
Excluded: 1020 
Non-relevant, n=889 (OA not an index 
disease, multimorbidity)  
Post-surgical OA study, n=131 
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Concept note/ Editorial=4 
Duplication of study findings=5 
No clinical comorbidity = 5 
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Figure 2 Prevalence of number of any comorbidities in people with OA across the study design 
 
[Number of studies in each group; Any comorbidity – Total (21), Cross sectional (16), case control (1), cohort (4); One comorbidity- Total (18), Cross sectional (13), case control (2), cohort (3); 
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Figure 3 Prevalence (%) of comorbidities in people with OA (disease and system specific) 
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#Only systemic comorbidities information has been used from the study by Saltzman et al 2006 in all estimates; NOS- Newcastle Ottawa Scale; M-H Mantel 
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